ESMO 2022 on the Phase 3 RATIONALE-301 Study: Tislelizumab OS Benefit vs. Sorafenib as 1L Treatment for Unresectable HCC

By ecancer FEATURING Richard S. Finn
By ecancer FEATURING Richard S. Finn
37 views
September 30, 2022
Comments 0
Login to view comments. Click here to Login